… on NK cells and T-lymphocytes, HLA-E inhibits their cytotoxic function. Monalizumab (mona)
is a … Monalizumab (mona) is a human IgG4 antibody targeting the NKG2A receptor. Methods …

… T-cells and NK cells. A phase I/II non-randomised trial showed promising data for the combination
of monalizumab and cetuximab in patients … of single-agent monalizumab in SCCHN. In …

… : Monalizumab (Mona) is an immune checkpoint inhibitor targeting NKG2A receptors expressed
on tumor-infiltrating CD8 T and Natural Killer (NK cells). … Remaining patients are not yet …

… NKG2A blockade promotes anti-tumor immunity and may provide additional … of monalizumab
and cetuximab with the addition of durvalumab (cohort 3) in first-line treatment of patients …

… In a cohort of 40 patients of heavily pretreated SCCHN patients, monalizumab and
cetuximab … An additional R/M SCCHN cohort of 40 patients who received both platinum-based …

… cell carcinoma (HNSCC) cell lines and the efficacy of monalizumab, an NKG2A inhibitor, in
promoting NK cell … apply molecular enrichment based on HLA-E-positivity in patient selection. …

… ) with 40 patients planned in each cohort. All patients received monalizumab intravenously
750 … Here we present updated analysis for Cohort 2 and an exploratory analysis of all patients …

… monalizumab is being developed for the treatment of various cancers, including … negative
recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). In the …

… cell carcinoma (RCC, n=75), we observed NKp46 + NK cells … CRC patients with liver metastasis
(n=101), high CD94 + cell … and T cells that are present in close contact to tumor cells. As …

… in previously treated squamous cell carcinoma of the head … -tumor efficacy of monalizumab
in cocultures of NK cells with … the combination of monalizumab and cetuximab in patients with …